- Home
- AKA vs SGMT Comparison
AKA vs SGMT Comparison
Compare AKA & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- SGMT
- Stock Information
- Founded
- AKA 2018
- SGMT 2006
- Country
- AKA United States
- SGMT United States
- Employees
- AKA N/A
- SGMT N/A
- Industry
- AKA Catalog/Specialty Distribution
- SGMT
- Sector
- AKA Consumer Discretionary
- SGMT
- Exchange
- AKA Nasdaq
- SGMT Nasdaq
- Market Cap
- AKA 126.7M
- SGMT 128.5M
- IPO Year
- AKA 2021
- SGMT 2023
- Fundamental
- Price
- AKA $15.11
- SGMT $2.58
- Analyst Decision
- AKA Buy
- SGMT Strong Buy
- Analyst Count
- AKA 4
- SGMT 6
- Target Price
- AKA $24.50
- SGMT $25.67
- AVG Volume (30 Days)
- AKA 9.8K
- SGMT 333.5K
- Earning Date
- AKA 03-06-2025
- SGMT 03-12-2025
- Dividend Yield
- AKA N/A
- SGMT N/A
- EPS Growth
- AKA N/A
- SGMT N/A
- EPS
- AKA N/A
- SGMT N/A
- Revenue
- AKA $574,697,000.00
- SGMT N/A
- Revenue This Year
- AKA $6.56
- SGMT N/A
- Revenue Next Year
- AKA $4.25
- SGMT N/A
- P/E Ratio
- AKA N/A
- SGMT N/A
- Revenue Growth
- AKA 5.21
- SGMT N/A
- 52 Week Low
- AKA $8.89
- SGMT $2.39
- 52 Week High
- AKA $33.73
- SGMT $7.38
- Technical
- Relative Strength Index (RSI)
- AKA 54.32
- SGMT 25.28
- Support Level
- AKA $13.00
- SGMT $3.89
- Resistance Level
- AKA $16.90
- SGMT $4.24
- Average True Range (ATR)
- AKA 0.94
- SGMT 0.29
- MACD
- AKA 0.35
- SGMT -0.08
- Stochastic Oscillator
- AKA 69.05
- SGMT 3.49
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.